A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-17

Study Completion Date

2023-02-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if an investigational drug, AT-100, is safe and tolerated by adults who have severe corona virus disease 2019 (COVID-19) or respiratory failure secondary to severe community acquired pneumonia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bronchopulmonary PK of AT-527 (R07496998)

NCT04877769

Healthy Volunteer Study

COMPLETED PHASE1

Study of OsrhAAT or Placebo in Healthy Volunteers

NCT05315921

Emphysema Secondary to Congenital AATD

UNKNOWN PHASE1

COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2

NCT04858451

COPD Bronchiectasis

TERMINATED PHASE2

Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

NCT04472494

COVID-19 SARS-CoV-2

TERMINATED PHASE2

Study in Healthy Adults to Quantify Lung Deposition and Distribution of Radio-labelled S-770108 Inhalation Powder Formulation Delivered by a Novel Inhaler Device

NCT04631354

Healthy Volunteer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Undefined

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Phase 1b portion is a dose escalation study to establish the safest \& most tolerable AT-100 dose.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AT-100 75 mg

Once daily AT-100 via intratracheal administration for up to 7 doses.

Group Type EXPERIMENTAL

AT-100

Intervention Type BIOLOGICAL

reconstituted AT-100 for intratracheal administration

AT-100 150 mg

Once daily AT-100 via intratracheal administration for up to 7 doses, if the prior dose level was safe \& tolerated.

Group Type EXPERIMENTAL

AT-100

Intervention Type BIOLOGICAL

reconstituted AT-100 for intratracheal administration

AT-100 75 mg or 150 mg (Optional Cohort)

Once daily AT-100 via intratracheal administration for up to 7 doses, at the highest safe \& tolerated dose as determined by the prior 2 dosing levels.

Group Type EXPERIMENTAL

AT-100

Intervention Type BIOLOGICAL

reconstituted AT-100 for intratracheal administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AT-100

reconstituted AT-100 for intratracheal administration

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

(rhSP-D)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The subject is an adult ≥18 years of age.
2. The subject has documented, laboratory-confirmed SARS-CoV-2 infection within 2 weeks prior to enrollment, or meets criteria for severe community acquired pneumonia (CAP) specified in inclusion 3 below.
3. The subject has severe SARS-CoV-2 infection requiring intubation and mechanical ventilation. Or, the subject is admitted for severe CAP with respiratory failure as demonstrated by the following:

3\. i. Respiratory failure requiring intubation and mechanical ventilation, and 3. ii. A clinical diagnosis of CAP that includes radiographic findings of new pulmonary infiltrate(s) consistent with CAP plus any one of the following on admission to the hospital: 3. ii. 1. Fever (Temperature \> 38.0°C), 3. ii. 2. Hypothermia (Temperature \< 36.0°C), 3. ii. 3. Leukocytosis with White Blood Cells (WBC) \> 10,000 cells/µL or immature band forms \> 10%, 3. ii. 4. Leukopenia with WBC \< 4,000 cells/µL, or 3. ii. 5. Hypotension Mean Arterial Pressure (MAP) \< 70 mmHg, requiring the initiation of vasopressor support.

4\. The subject has been receiving mechanical ventilation for \<72 hours. 5. The subject is receiving mechanical ventilation due to respiratory disease that is primarily due to SARS-CoV-2 infection or CAP.

6\. The subject, or legally authorized representative if acting on the subject's behalf, is able to provide informed consent.

Exclusion Criteria

1. The subject refuses to participate, or the subject's legally authorized representative acting on the subject's behalf refuses the subject's participation.
2. The subject is pregnant or breastfeeding.
3. The subject is anticipated to be transferred to another hospital that is not a study site within 36 hours of enrollment.
4. The subject has received or is receiving extracorporeal membrane oxygenation (ECMO) treatment for COVID-19 or CAP treatment.
5. The subject has Human Immunodeficiency virus (HIV) under highly active antiretroviral therapy (HAART).
6. The subject has cancer and is receiving chemotherapy treatment at any time during trial duration, or has received chemotherapy treatment within 30 days of trial enrollment.
7. The subject has a prior history of lung transplant, lobectomy, or other significant lung surgeries that would indicate an already compromised lung.
8. The subject has known pulmonary air leaks, such as pneumothorax and pneumomediastinum.
9. Concurrent enrollment in an investigational product, device, or treatment trial or is projected to participate in any other trial that alters the standard of care during the period of this study
10. The subject has a known allergy, sensitivity, or contraindication to any component of the test article (AT-100).
11. The subject has any active do not resuscitate (DNR)-Comfort Care (CC) order in place. Subjects with an active DNR-Comfort Care Arrest (CCA) are not excluded.
12. The subject's intubation, re-intubation, or remaining on intubation is not per clinical standard-of-care and is solely for the purposes of administration of study drug.
13. The subject has any condition or is in a situation in which, in the Investigator's judgement, puts the subject at significant risk, could confound the trial results, or may significantly interfere with the subject's trial participation.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No